Forum de l'union médicale: Tunisie,Algérie,Maroc

Soyez le bienvenu sur FUMED (Forum de l'Union Médicale).


Espace de discussion scientifique pour les praticiens médicaux et para-médicaux des pays maghrébins francophones (Algérie, Tunisie, Maroc)

Do you like FUMED

Connexion

Récupérer mon mot de passe




















Pour établir un PARTENARIAT avec FUMED contactez l'administration du forum en cliquant ici:




 free counters

Aliskiren (Rasilez®)

Partagez

M@NEL
Super-modératrice
Super-modératrice

Féminin Messages : 1006
Date d'inscription : 12/08/2009
Age : 27
Localisation : Algérie
Emploi : Ph

Aliskiren (Rasilez®)

Message par M@NEL le Jeu 04 Nov 2010, 20:40


[Vous devez être inscrit et connecté pour voir cette image]

Classe pharmacothérapeutique : Inhibiteur de la rénine, c


L'aliskiren est un inhibiteur direct de l'activité de la rénine humaine, non peptidique, sélectif et puissant, actif par voie orale.


comment ça marche

En inhibant l'enzyme rénine, l'aliskiren inhibe le SRA au point d'activation, en bloquant la conversion de l'angiotensinogène en angiotensine I et en réduisant les taux d'angiotensine I et d'angiotensine II. Alors que d'autres inhibiteurs du SRA (IEC et antagonistes des récepteurs de l'angiotensine II (ARA)) entraînent, par compensation, une élévation de l'activité rénine plasmatique (ARP), le traitement par l'aliskiren diminue l'ARP d'environ 50 à 80 % chez les patients hypertendus. Des réductions similaires ont été observées lorsque l'aliskiren a été associé à d'autres antihypertenseurs. Les conséquences cliniques des différences d'effet ne sont pas connues

dr remzi 06
Progresse
Progresse

Masculin Messages : 19
Date d'inscription : 20/03/2010
Age : 29
Localisation : Alger
Emploi : Etudiant

Re: Aliskiren (Rasilez®)

Message par dr remzi 06 le Ven 19 Nov 2010, 12:13

Merci

ECHOCADIOGRAPHEUR
Membre hyper-actif
Membre hyper-actif

Masculin Messages : 975
Date d'inscription : 01/05/2010
Age : 49
Localisation : EL JADIDA MAROC
Emploi : MEDECIN PRIVE

Re: Aliskiren (Rasilez®)

Message par ECHOCADIOGRAPHEUR le Ven 24 Déc 2010, 21:00

RESPONSES TO ALISKIREN/HCTZ VERSUS AMLODIPINE ON PERIPHERAL AND CENTRAL BLOOD
PRESSURE IN AFRICAN AMERICAN PATIENTS WITH STAGE 2 HYPERTENSION

ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Central Blood Pressure Drugs and Genes
Abstract Category: Hypertension
Presentation Number: 1240-103
Authors: Keith Ferdinand, James Pool, Richard Weitzman, Das Purkayastha, Raymond Townsend, Emory University, Decatur, GA


Background: In African American (AA) men, central BP may better reflect the levels of vascular burden than peripheral (brachial) BP. There is
a paucity of data on the efficacy of antihypertensive agents on central pressure in AA. This 8-week prospective, multicenter, randomized, doubleblind
study of AA patients with stage 2 (MSSBP ≥ 160 mmHg and < 200 mmHg) hypertension evaluated the brachial and central BP responses of
treatment with the single pill combination aliskiren/HCTZ (A/H) compared with amlodipine (AML).


Methods: Following a 1-4 week washout eligible patients ≥18 years (mean age= 52.6), received either A/H150/12.5 mg (n=166) or AML 5 mg
(n=166) for 1 week; force titrated to A/H 300/25 or AML 10 mg for 7 weeks. Primary efficacy was change from baseline in MSSBP at Week 8. A
substudy (n=52) evaluated treatment differences in central BP.
Results: At week 8, both treatments provided significant reductions in MSSBP from baseline [-28.6 ±17.95, -28.2 ± 13.17 mm Hg] in the A/H
and AML arms, with no significant differences between treatments. However, A/H significantly reduced (p <0.05) central SBP and increased pulse
pressure amplification ratio (brachial/central) vs AML (Table). Both treatments were well tolerated.


Conclusion: Despite similar reductions in peripheral SBP with the 2 treatments, reductions in central systolic pressure was significantly in favor of
A/H. Our findings suggest an important new treatment option since central pressure is considered an important risk factor in AA patients.

ECHOCADIOGRAPHEUR
Membre hyper-actif
Membre hyper-actif

Masculin Messages : 975
Date d'inscription : 01/05/2010
Age : 49
Localisation : EL JADIDA MAROC
Emploi : MEDECIN PRIVE

Re: Aliskiren (Rasilez®)

Message par ECHOCADIOGRAPHEUR le Ven 24 Déc 2010, 21:01

RESPONSES TO ALISKIREN/HCTZ VERSUS AMLODIPINE ON PERIPHERAL AND CENTRAL BLOOD
PRESSURE IN AFRICAN AMERICAN PATIENTS WITH STAGE 2 HYPERTENSION

ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Central Blood Pressure Drugs and Genes
Abstract Category: Hypertension
Presentation Number: 1240-103
Authors: Keith Ferdinand, James Pool, Richard Weitzman, Das Purkayastha, Raymond Townsend, Emory University, Decatur, GA


Background: In African American (AA) men, central BP may better reflect the levels of vascular burden than peripheral (brachial) BP. There is
a paucity of data on the efficacy of antihypertensive agents on central pressure in AA. This 8-week prospective, multicenter, randomized, doubleblind
study of AA patients with stage 2 (MSSBP ≥ 160 mmHg and < 200 mmHg) hypertension evaluated the brachial and central BP responses of
treatment with the single pill combination aliskiren/HCTZ (A/H) compared with amlodipine (AML).


Methods: Following a 1-4 week washout eligible patients ≥18 years (mean age= 52.6), received either A/H150/12.5 mg (n=166) or AML 5 mg
(n=166) for 1 week; force titrated to A/H 300/25 or AML 10 mg for 7 weeks. Primary efficacy was change from baseline in MSSBP at Week 8. A
substudy (n=52) evaluated treatment differences in central BP.
Results: At week 8, both treatments provided significant reductions in MSSBP from baseline [-28.6 ±17.95, -28.2 ± 13.17 mm Hg] in the A/H
and AML arms, with no significant differences between treatments. However, A/H significantly reduced (p <0.05) central SBP and increased pulse
pressure amplification ratio (brachial/central) vs AML (Table). Both treatments were well tolerated.


Conclusion: Despite similar reductions in peripheral SBP with the 2 treatments, reductions in central systolic pressure was significantly in favor of
A/H. Our findings suggest an important new treatment option since central pressure is considered an important risk factor in AA patients.

Contenu sponsorisé

Re: Aliskiren (Rasilez®)

Message par Contenu sponsorisé


    La date/heure actuelle est Lun 27 Fév 2017, 03:04